MARATTO

article · Pan African Medical Journal

Caregivers' beliefs about hydroxyurea influence its usage among children with sickle cell disease: a cross-sectional study in Dar-es-Salaam, Tanzania

20252 citationsOpen accessThe University of Dodoma

Abstract

Introduction: hydroxyurea (HU) is a proven, safe, and effective treatment for sickle cell disease (SCD) but is underutilized in Tanzania. Caregivers´ beliefs influence medication usage in children with chronic diseases. This study assessed caregivers´ beliefs about HU and their effect on HU use among children with SCD in Dar-es-Salaam. Methods: a cross-sectional study enrolled 374 caregivers from four hospitals in Dar-es-Salaam. We adapted the "Belief About Medication Questionnaire" to assess caregivers´ beliefs about HU necessity and concerns. Scores of ≥15 indicated high necessity/concerns. Caregivers were categorized into four belief patterns: positive (high necessity, low concerns), negative (low necessity, high concerns), ambivalent (high necessity, high concerns), and indifferent (low necessity, low concerns). Results: seventy percent of caregivers reported HU usage, 63% exhibited positive beliefs, with 95% of them reporting HU use. Caregivers with an indifferent belief category made up 43% of those with non-positive beliefs, and only 7% of them reported HU use. Thirty-eight percent of caregivers were concerned about HU's long-term effects, whereas 67% perceived that HU protects their children´s health from worsening. Caregivers with positive beliefs were 14 times more likely to report HU use than those with indifferent HU beliefs (IRR 14.3, 95% CI: 5.5 - 36.9). Participants from national hospitals were three times more likely to have positive beliefs than those attending regional hospitals (aOR 3.3, 95% CI 2.1 - 5.1). Conclusion: health-care level and caregivers´ education impact HU beliefs and use. Targeted interventions to address specific obstacles across different caregiver subgroups are essential to improve HU beliefs and usage.

Research topics

  • Hemoglobinopathies and Related Disorders
  • Iron Metabolism and Disorders
  • Blood groups and transfusion

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.11604/pamj.2025.52.31.45975

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.